| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Research Overview
High Competition and Price Pressures are Beleaguering European Generic Drug Manufacturers
Competition in the generic drugs market continues to intensify as the industry
adjusts to increased pressures to contain healthcare costs. Also Generic
pharmaceutical manufacturers in Europe are experiencing downward price
pressures due to high competition and some hampering regulations by the
governments.
Patent Expiries and Government Initiatives is Driving the Market
Imminent key patent expiries are one of the key growth drivers with high
impact throughout the forecast period 2004-2011. A significant number of
blockbuster drugs are expected to lose patent protection. According to
industry sources, patented products with total sales of more than $20.00
billion are likely to lose patent protection during 2004-2006. Also strong
efforts from individual European governments and other healthcare payors to
contain healthcare costs are boosting the use of generics. In mature European
markets such as the United Kingdom and Germany, generics already represent
over 30 per cent of the total prescription volume. Governments of France,
Spain and Italy are also taking initiatives and implementing new regulations
to improve the generic penetration into individual countries.
Increasing Favourable Environment for Generic Drug Manufacturers
Germany, the Netherlands and the United Kingdom are the developed generic
markets. In some European countries, there is a market for both branded
generics and products sold under generic name. However, there are countries
where only the branded generic drugs market is established. French generic
drugs market is now expanding with the highest growth rate among the top five
European countries. On the other hand, the Italian generic drugs market is
witnessing a relatively slow growth. The issues with patent and data
exclusivity have delayed opportunities in both France and Italy. The expansion
of EU is likely to increase additional opportunities for generic drug
manufacturers and is also expected to allow better centralisation of
regulatory processes.
TABLE OF CONTENTS
- 1. Executive Summary
- 1. Executive Summary
- 1. Summary of Generic Drugs Market in Top Five European Countries
- 2. Abbreviations and Key Definitions
- 1. Abbreviations
- 2. Key Definitions (Source: European Generic Medicines Association)
- 3. Introduction
- 1. Introduction
- 1. Overview
- 2. Regulations
- 4. Market Dynamics
- 1. Key Industry Challenges
- 1. Key Industry Challenges
- 2. Key Market Drivers and Restraints
- 1. Key Drivers
- 2. Key Restraints
- 5. Market Engineering Research for European Generic Drugs Market
- 1. Market Engineering Research for European Generic Drugs Market
- 1. Background
- 2. Market Engineering Research Measurement System
- 3. Total European Generic Drugs Market
- 4. Geographic Trends
- 5. Generic Drugs Market in Germany
- 6. Generic Drugs Market in the United Kingdom
- 7. Generic Drugs Market in France
- 8. Generic Drugs Market in Spain
- 9. Generic Drugs Market in Italy
- 6. Competitive Analysis
- 1. Competitive Analysis
- 1. Competitive Analysis
- 2. Company Profiles
- 7. Strategic Analysis and Recommendations
- 1. Strategic Analysis and Recommendations
- 1. Strategic Recommendation
- 2. SWOT Analysis - German Generic Drugs Market
- 3. SWOT Analysis - United Kingdom Generic Drugs Market
- 4. SWOT Analysis - French Generic Drugs Market
- 5. SWOT Analysis - Spanish Generic Drugs Market
- 6. SWOT Analysis - Italian Generic Drugs Market
- 7. Attractiveness of Generic Markets
- 8. Three Levels of Strategies
- 8. Decision Support Databases
- 1. Decision Support Databases
- 1. Government Healthcare Expenditure
- 2. Private Healthcare Expenditure
- 3. Total Healthcare Expenditure
- 4. Per Capita Healthcare Expenditure
- 5. Pharmacists
|
